

# NANOBIOTIX – €20m ABB (primary shares) – July 2020



July 2020

**NANOBIOTIX**  
EXPANDING LIFE

Capital increase  
**€20m**

Joint Bookrunner

Demand split @ €6.10



Strictly confidential

## Overview of NANOBIOTIX

- NANOBIOTIX, founded in 2003, is a France-based clinical-stage company pioneering nanomedicine
- The Company has developed a proprietary nanotechnology based on the physical mode of action of nanoparticles which aims at extending the benefits of radiotherapy to cancer patients
- Its lead product, NBTXR3, is designed to enhance the overall efficiency of the radiotherapy by locally amplifying intratumor cell killing effect of the radiation
  - NBTXR3 announced positive Phase II/III results for Soft Tissue Sarcoma; first market authorization process (CE Mark) in Europe obtained in April 2019.
  - The Company is now prioritizing NBTXR3 for locally advanced head and neck cancers; ongoing Phase I dose escalation and expansion have shown high overall response rates; Fast Track designation from FDA received in February 2020; global Phase III trial planned.
  - Other Phase I/II trials of NBTXR3 ongoing for liver, prostate and rectum cancers
  - A collaboration with MD Anderson was signed in December 2018 for nine additional US trials of NBTXR3; the first one for pancreatic cancer is planned to begin in Q3 2020.
  - NBTXR3 is also being evaluated for in situ vaccination and immunology
- NBTXR3 is compatible with standard radiotherapy treatments and intended to potentially treat various cancers through multiple routes of administration

## Transaction highlights

- On July 28, Nanobiotix launched post market close a capital increase of c. €20m via an ABB
- Strong momentum during bookbuilding thanks to a wall-crossing of c. 30 investors ahead of the launch to secure its success:
  - Crossover round inclusive of US and EU specialized biotech investors Perceptive Advisors and The Invus Group along with other new investors and existing shareholders
  - The placement was oversubscribed
- ODDO BHF generated c. 33% of the demand at subscription price (€6.10)
- The Company intends to use the net proceeds from the Reserved Offering to:
  - Move forward with lead program in head and neck cancers with the start of the global phase III that should lead to the US and EU registrations
  - Complete the escalation of the immune-oncology phase I basket-trial
  - Extend the Company's financial visibility

## Transaction details

<b>Listing</b>	▪ Euronext Paris
<b>Pre-announcement market cap</b>	▪ c. €162m
<b>Total offer size</b>	▪ €20m ▪ 3,300,000 new shares ▪ 15% of existing shares
<b>Subscription price</b>	▪ €6.10
<b>Discount</b>	▪ 14.5% vs. VWAP 1 day ▪ 14.1% vs. last closing price
<b>Announcement</b>	▪ 27 July 2020
<b>Settlement / Delivery</b>	▪ 30 July 2020
<b>Lock up</b>	▪ 90 days for the company
<b>ODDO BHF role</b>	▪ Joint Bookrunner

## Transaction timetable

